In this study, we conducted comprehensive drug target MR analysis to evaluate the causal effects of the most commonly prescribed lipid-lowering drug classes including HMGCR, PCSK9, and NPC1L1 inhibitors on sarcopenia risk. This evidence concerns the gene PCSK9 and sarcopenia.